Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

MLA

Shan Su, et al. “Assessment of Anti-PD-(L)1 for Patients with Coexisting Malignant Tumor and Tuberculosis Classified by Active, Latent, and Obsolete Stage.” BMC Medicine, vol. 19, no. 1, Dec. 2021, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12916-021-02194-z.

APA

Shan Su, Mei-Feng Ye, Xiao-Ting Cai, Xue Bai, Zhi-Hao Huang, Si-Cong Ma, Jian-Jun Zou, Yu-Xiang Wen, Li-Juan Wu, Xue-Jun Guo, Xian-Lan Zhang, Wen-Chang Cen, Duo-Hua Su, Hui-Yi Huang, & Zhong-Yi Dong. (2021). Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. BMC Medicine, 19(1), 1–11. https://doi.org/10.1186/s12916-021-02194-z

Chicago

Shan Su, Mei-Feng Ye, Xiao-Ting Cai, Xue Bai, Zhi-Hao Huang, Si-Cong Ma, Jian-Jun Zou, et al. 2021. “Assessment of Anti-PD-(L)1 for Patients with Coexisting Malignant Tumor and Tuberculosis Classified by Active, Latent, and Obsolete Stage.” BMC Medicine 19 (1): 1–11. doi:10.1186/s12916-021-02194-z.